Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Predictive Oncology’s SEC disclosures can feel like running a clinical trial of your own—hundreds of pages on AI-driven drug screens, biobank valuations, and FDA-regulated devices. Whether you’re tracking STREAMWAY revenue or the PEDAL platform’s impact on R&D spend, the details hide deep inside 10-K footnotes and 8-K exhibits.
Stock Titan solves that problem. Our AI-powered summaries translate each Predictive Oncology annual report 10-K simplified, every quarterly earnings report 10-Q filing, and each Predictive Oncology 8-K material events explained into clear, actionable language. Need real-time alerts? We surface Predictive Oncology Form 4 insider transactions in real time, flagging executive stock sales before they hit the news. The platform covers the full spectrum—proxy statement executive compensation tables, registration statements, and even niche S-8 filings—updated the minute EDGAR posts.
Looking for specific answers? Use our search prompts like “understanding Predictive Oncology SEC documents with AI” or “Predictive Oncology earnings report filing analysis” and jump straight to AI-generated highlights: segment revenue trends, cash runway projections, and risk-factor changes. Monitor Predictive Oncology insider trading Form 4 transactions, compare R&D outlays quarter-over-quarter, or download clean tables for your own models. With comprehensive filing coverage, plain-English explanations, and machine-learning insights, Stock Titan turns complex biotech disclosures into practical intelligence investors actually use.
Predictive Oncology Inc. disclosed material transactions tied to private placements that include cash and cryptocurrency investments subject to customary closing conditions. The company agreed to issue placement agent warrants to purchase approximately 3.3 million shares exercisable at $0.7751 for five years and to pay a 5% cash fee to the placement agent for gross cash proceeds (excluding digital-asset proceeds). Strategic advisor warrants equal to approximately 20.3 million shares (about 7% of the securities sold) will be issued, exercisable at $0.7751 for five years and carrying a beneficial ownership cap of 4.99% (or optionally 9.99%). A Side Letter with DCI Foundation requires DCI to cure issues with locked crypto within five business days and to deliver an additional 20% of ATH tokens bought on the open market within 30 days of each purchase. The company amended bylaws effective September 26, 2025 to cap the board at seven directors. Various form agreements and exhibits were filed.
Predictive Oncology, Inc. filed a Form 8-K reporting a material event that includes a Certificate of Amendment to its certificate of incorporation and an attached press release dated
Predictive Oncology director Nancy Chung-Welch received a grant of 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting and the award vests in full on October 31, 2025, subject to continued service through that date. The transaction is reported as an acquisition at a $0.00 price, leaving Ms. Chung-Welch with 83,993 shares beneficially owned after the grant.
Predictive Oncology insider grant and holdings summary
Director Daniel E. Handley was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting, and the award is scheduled to vest in full on October 31, 2025, subject to continued service through that date. The RSUs were granted at a recorded price of $0.00. Following the grant, the reporting person beneficially owns 81,698 shares. The Form 4 indicates a single reporting person filed for this transaction.
Predictive Oncology Inc. (POAI) reported a non‑derivative grant to director Matthew Hawryluk consisting of 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts into one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, contingent on continued service through that date. After the grant, Mr. Hawryluk is recorded as beneficially owning 74,168 shares of common stock. The Form 4 was signed by an attorney‑in‑fact on behalf of the reporting person on 09/11/2025.
Predictive Oncology Inc. (POAI) director Veena Rao was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock on vesting, and the grant was recorded at a $0.00 acquisition price. Following the award, Ms. Rao's reported beneficial ownership increased to 73,797 shares. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through the vesting date. The filing identifies the transaction as an acquisition by the reporting person in their capacity as a director and shows the report was submitted by one reporting person.
Predictive Oncology Inc. director Gregory St. Clair Sr. was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share upon vesting and the grant carries a $0.00 purchase price. The RSUs vest in full on October 31, 2025, subject to continued service through that date. After the grant, the reporting person is shown as beneficially owning 85,882 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/11/2025.
Predictive Oncology Inc. (POAI) director Charles Lee Nuzum Sr. received a grant of 64,680 restricted stock units (RSUs) on 09/09/2025, according to this Form 4 filing. Each RSU represents the right to one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date. After the grant, the reporting person beneficially owns 94,587 shares. The filing indicates it was made by one reporting person and was signed via attorney-in-fact on 09/11/2025.
Predictive Oncology Inc. (POAI) reported a Form 4 showing that Joshua Blacher, serving as Interim CFO and an officer/director, was granted 97,000 restricted stock units (RSUs) on 09/09/2025. Each RSU represents the right to one share of common stock on vesting. The RSUs vest in full on October 31, 2025, subject to continued service through that date. Following the grant, Mr. Blacher is recorded as beneficially owning 97,000 shares directly from this award. The filing is signed 09/11/2025.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
